Table 1.
Major p16 functions in the variety of biological processes observed in different models and tissues.
Process | Model and/or Tissue | Potential Role/Function | References |
---|---|---|---|
Intervertebral disc damage | Mouse and human intervertebral disc tissues | P16 is a potential therapeutic target for intervertebral disc damage relief. | [48] |
Wound healing | P16-3MR model (fibroblasts, endothelial cells, and keratinocytes) | Accelerate wound closure and re-epithelialization | [43] |
Tumorigenesis and tumor suppression | Skin, bone, lung, liver, and brain cancer patients tissues and immunohistopathology | Implicated in tumor development, progression, and metastasis Predictive and prognostic marker Therapeutic target Increases chemosensitivity |
[39,40,41,42,72,105,106,107,108,111,112,134,135,136,150,151,152,153,168,169,170,205,206] |
Stem cell self-renewal and differentiation | Skin, lung, bone, brain, and heart stem cells | Balanced expression of p16 is a prerequisite for stem cells proliferation and differentiation. Therapeutic approach for maintenance of regenerative capacity |
[46,92,101,115,116,117,118,119,138,149,155,156,179] |
Cellular senescence | Primary mouse fibroblasts and melanocytes | Target for oncogene-induced senescence bypass and aging | [37,38] |
Bone homeostasis | P16-3MR and p16-INK-ATTAC mouse model | Maintenance of bone mass Orchestration of osteoblast and osteoclast function |
[123,132,133] |
Bone fracture healing | Geriatric Mouse model (p16-/- and WT) | P16-deletion stimulated osteoblastogenesis and vascularization and accelerated bone fracture healing | [138] |
Muscle injury | Acute muscle injury (AIM) mouse model | Tissue regeneration | [45] |
Osteoporosis | Ovariectomized p16-/- and WT mice | Potential therapeutic target to prevent estrogen-induced osteoporosis | [124,125,126,127,137] |
COPD | Lung alveolar and lung epithelial cells in mice and human | Implicated in COPD severity Potential therapeutic target |
[140,141,142,149] |
Cervical SCC and pulmonary SCC | Human cancer patients | Discriminating biomarker | [150] |
Oxidative stress | Fibroblasts, keratinocytes, and melanocytes | P16 regulates oxidative stress and ROS production as pRB-independent tumor suppression mechanism | [72,204] |
Mitochondrial biogenesis | Primary mouse fibroblasts, human melanocytes, A375 melanoma cells | P16 balances mitochondrial structure and function | [111] |
Alzheimer’s disease (AD) | Alzheimer’s disease patients and mouse model | Implicated in AD severity and development Therapeutic target |
[159,160,161,166] |
Lung injury | P16-/- and WT mouse model (lung epithelium) | P16 protects against lungs injury | [154] |
Cardiac fibrosis | p16-CreERT2-tdTomato mouse model | P16-positive cells removal induces cardiac fibrosis | [83] |
Myocardial Infarction | Mice | Indispensable for maintenance of cardiac function and cardiac remodeling after infarction | [181] |
Glucose metabolism and homeostasis | Super-INK4A/ARF mice model | Prevented the development of glucose intolerance with aging Protective role against age-induced insulin resistance |
[198] |
Liver fibrosis | INK-ATTAC mouse model | Therapeutic approach for treatment of liver fibrosis | [83,88,204] |
Fat metabolism | Mouse model and primary hepatocytes | Regulate fasting-induced fatty acid oxidation and lipid droplet accumulation in the liver | [201] |
Development | Young mice brain, heart, kidney, and liver | Dynamic p16 expression detected in embryonic mice organs, reflecting a potential role in embryonic development | [120] |